Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

(2012) Juanita M. Crook et al.   NEW ENGLAND JOURNAL OF MEDICINE

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

(2011) Emmanuel S. Antonarakis et al.   BJU INTERNATIONAL

Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents

(2011) Emmanuel S. Antonarakis et al.   CANCER

Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen Deprivation

(2010) Evan Y. Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy

(2008) Bruce J. Trock   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Natural History of Men Treated With Deferred Androgen Deprivation Therapy in Whom Metastatic Prostate Cancer Developed Following Radical Prostatectomy

(2007) Danil V. Makarov et al.   JOURNAL OF UROLOGY